Clinical Trial

The Effects of Waning of Botulinum Toxin in the Treatment of Cervical Dystonia

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The main treatment for cervical dystonia is botulinum toxin injections. However, some patients receiving this treatment after many years tend to experience short duration of benefit. Typically, botulinum toxin brands used in clinic are Botox or Xeomin. Another type of botulinum toxin is called Dysport (Ipsen Biopharmaceuticals), and Dysport may increase duration of benefit from the injections. The study is selecting patients from the investigator's clinics who are not satisfied with the duration of their treatment and are willing to switch to Dysport and the investigators will monitor if Dysport will increase the duration of benefit over a total of 3 treatments. A group of patients will be switched to Dysport while another group will remain on their original botulinum toxin formulation. The patients will be unaware of the treatment switch and hence are considered to be blinded. The investigators will not be blinded. Treatments are given every 3 months. All study visits will occur at the local sites of the 3 recruiting sites.
Trial Details
NCT Number NCT06886750
Lead Sponsor Western University, Canada
Collaborators: Manjog Enterprises Limited
Conditions Cervical Dystonia, Primary
Enrollment 45 participants
Start Date 2025-03-30
Primary Completion 2027-03-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-20